OSIMERTINIB INTERMEDIATES

VIDGASTECH provides Osimertinib Intermediates with superior purity and stability, supporting the synthesis of EGFR inhibitors for non-small cell lung cancer (NSCLC) treatment.

Additional Content with Keywords:
VIDGASTECH specializes in pharmaceutical-grade Osimertinib API intermediates, essential for the production of targeted oncology drugs used in EGFR-mutated NSCLC treatment. With strict GMP compliance, high-purity synthesis, and quality control, our intermediates enable efficient drug formulation and active pharmaceutical ingredient (API) manufacturing. As a trusted supplier of Osimertinib intermediates, we cater to global pharmaceutical companies developing next-generation lung cancer therapies. Contact us for bulk API intermediates and custom synthesis solutions.VIDGASTECH specializes in high-purity API intermediates, including 3-(2-chloropyrimidin-4-yl)-1-methyl-1H-indole (CAS: 1032452-86-0), Osimertinib, 4-fluoro-2-methoxy-5-nitroaniline (CAS: 1075705-01-9), (4-Fluoro-2-methoxy-5-nitrophenyl)-[4-(1-methyl-1H-indol-3-yl)-pyrimidin-2-yl]-amine (CAS: 1421372-94-2), and N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine. Our intermediates ensure precision and reliability for pharmaceutical research and advanced chemical synthesis.